How have LPCN shares performed in 2024?

Lipocine's stock was trading at $2.79 on January 1st, 2024. Since then, LPCN stock has increased by 70.6% and is now trading at $4.76. View the best growth stocks for 2024 here .

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our LPCN earnings forecast .

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.11. The specialty pharmaceutical company earned $0.22 million during the quarter.

When did Lipocine's stock split?

Lipocine's stock reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP) , Flexion Therapeutics (FLXN) , Trevena (TRVN) , Heat Biologics (HTBX) , Rigel Pharmaceuticals (RIGL) , Inovio Pharmaceuticals (INO) , SCYNEXIS (SCYX) , Dynavax Technologies (DVAX) , Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX) .

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LPCN

Lipocine (LPCN) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free LPCN Stock Alerts

$4.76

-0.60 (-11.19%)

(As of 05:43 PM ET)

Compare

Today's Range: $4.68
▼
$5.30
50-Day Range: $3.58
▼
$6.51
52-Week Range: $2.31
▼
$7.15

Volume: 37,037 shs
Average Volume: 63,083 shs
Market Capitalization: $25.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Lipocine alerts:

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Lipocine Stock (NASDAQ:LPCN)

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1154 for postpartum depression; LPCN 2101 for women with epilepsy; and LPCN 1148, a novel prodrug of testosterone, testosterone laurate for the management of decompensated cirrhosis. It also develops LPCN 1144, an oral prodrug of androgen receptor modulator for the treatment of non-cirrhotic non-alcoholic steatohepatitis, which has completed Phase II testing; LPCN 1111, an oral TRT product of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical testing; and LPCN 1107, an oral hydroxy progesterone caproate product for the prevention of recurrent preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

LPCN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LPCN Stock News Headlines

April 12, 2024 | msn.com

Lipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAs

April 11, 2024 | finanznachrichten.de

Lipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 11, 2024 | fr.investing.com

Lipocine annonce les résultats positifs d'une étude sur le traitement de l'obésité

April 11, 2024 | markets.businessinsider.com

Lipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With Obesity

April 11, 2024 | finance.yahoo.com

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

April 11, 2024 | prnewswire.com

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

April 11, 2024 | americanbankingnews.com

StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN)

April 16, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 28, 2024 | finanznachrichten.de

Lipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

March 28, 2024 | markets.businessinsider.com

Lipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 Study

March 28, 2024 | prnewswire.com

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

March 25, 2024 | finance.yahoo.com

Cirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight

March 25, 2024 | prnewswire.com

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

March 7, 2024 | investorplace.com

LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023

March 7, 2024 | seekingalpha.com

Lipocine GAAP EPS of -$3.14

March 7, 2024 | prnewswire.com

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

March 6, 2024 | finance.yahoo.com

Lipocine to Present at 36th Annual Roth Conference

February 6, 2024 | finance.yahoo.com

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

February 2, 2024 | finanznachrichten.de

Lipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals

February 2, 2024 | fr.investing.com

Lipocine transfère la commercialisation de TLANDO à Verity Pharma

February 2, 2024 | finance.yahoo.com

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

January 18, 2024 | marketwatch.com

Lipocine Shares Rise Premarket on Tlando Licensing Deal

January 18, 2024 | msn.com

Lipocine licenses Tlando testosterone therapy to Verity Pharma

January 18, 2024 | markets.businessinsider.com

Lipocine Signs TLANDO Franchise License Deal With Verity Pharma

January 18, 2024 | finance.yahoo.com

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

December 19, 2023 | finance.yahoo.com

Lipocine to Present at Biotech Showcase 2024

See More Headlines

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LPCN
CUSIP: N/A
CIK: 1535955
Web: www.lipocine.com
Phone: (801) 994-7383
Fax: 801-994-7388
Employees: 17
Year Founded: 1997

Profitability

EPS (Most Recent Fiscal Year): ($3.0503)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-16,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.28%
Return on Assets: -58.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.69
Quick Ratio: 8.69

Sales & Book Value

Annual Sales: $500,000.00
Price / Sales: 56.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.83 per share
Price / Book: 1.40

Miscellaneous

Outstanding Shares: 5,320,000
Free Float: 5,040,000
Market Cap: $28.49 million
Optionable: No Data
Beta: 1.05

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Mahesh V. Patel Ph.D. (Age 67)
Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Comp: $598.91k
Ms. Krista Fogarty (Age 56)
Principal Accounting Officer & Corporate Controller
Comp: $268.12k
Dr. Nachiappan Chidambaram Ph.D. (Age 54)
Senior Vice President of Research & Development
Comp: $311.17k
Mr. Logan Morse (Age 54)
Vice President of Sales, Marketing & Operations
Comp: $413.58k
Mr. Morgan R. Brown CPA (Age 56)
M.B.A., Corporate Secretary
Comp: $472.45k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LPCN Stock Analysis - Frequently Asked Questions

How have LPCN shares performed in 2024?: Lipocine's stock was trading at $2.79 on January 1st, 2024. Since then, LPCN stock has increased by 70.6% and is now trading at $4.76.
View the best growth stocks for 2024 here.
When is Lipocine's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our LPCN earnings forecast.
How were Lipocine's earnings last quarter?: Lipocine Inc. (NASDAQ:LPCN) announced its quarterly earnings data on Thursday, March, 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.11. The specialty pharmaceutical company earned $0.22 million during the quarter.
When did Lipocine's stock split?: Lipocine's stock reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX).
How do I buy shares of Lipocine?: Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LPCN) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial